The doctors' body urged him to bring all medicines under the national list of essential medicines (NLEM) stating that as of now only l5 per cent of them are in the list.
This leaves 85 per cent medicines, which are as essential as other drugs, out of the NLEM hence vulnerable to exploitative pricing, Dr G S Grewal and Dr Arun Mitra of the alliance said in the letter to the prime minister.
The prices of all essential medicines should be those of hospital prices, which are far less than the MRP mentioned on these.
The body has proposed that the prices of the drugs, after including all the medicines in NLEM, and implants used in healthcare should be calculated as per cost accountancy only.
"No other method can lead to justifiable fixation of prices of drugs. Also, the profit margin on the cost thus calculated should not be more than l0 per cent for the wholesaler and 20 per cent for the retailer which is already in practice. No other profit should be given to the health provider facility," they suggested.
"The implants or drugs have no label of hospital price on them. It has only one label MRP. This difference is used either by retailer or by a professional for making profit.
"In some cases, patients may be given discount of up to 10 per cent but still the profit margin is very high. This is in a way excess charge levied from the patient," the letter said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
